OptimizeRx (OPRX) Projected to Post Quarterly Earnings on Thursday

OptimizeRx (NASDAQ:OPRX) is anticipated to release its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect OptimizeRx to post earnings of $0.23 per share and revenue of $30.9150 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

OptimizeRx Trading Down 0.9%

NASDAQ:OPRX opened at $7.32 on Wednesday. The company has a market capitalization of $136.44 million, a PE ratio of 18.48 and a beta of 1.20. OptimizeRx has a 52-week low of $3.99 and a 52-week high of $22.25. The stock’s 50 day moving average price is $10.84 and its 200 day moving average price is $14.90. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20.

Institutional Trading of OptimizeRx

A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC purchased a new position in OptimizeRx in the fourth quarter worth $535,000. Inspire Investing LLC purchased a new position in shares of OptimizeRx in the 4th quarter valued at about $1,175,000. Engineers Gate Manager LP purchased a new position in shares of OptimizeRx in the 4th quarter valued at about $228,000. Boothbay Fund Management LLC lifted its stake in shares of OptimizeRx by 53.1% in the fourth quarter. Boothbay Fund Management LLC now owns 73,488 shares of the company’s stock valued at $901,000 after purchasing an additional 25,502 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in OptimizeRx by 16.9% during the fourth quarter. Bridgeway Capital Management LLC now owns 69,029 shares of the company’s stock worth $846,000 after buying an additional 10,000 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OPRX has been the topic of a number of research reports. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Citizens Jmp lifted their price objective on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Stephens lowered their price target on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a report on Monday, November 17th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.